Hospital Variation and Characteristics of Implantable Cardioverter-Defibrillator Use in Patients With Heart Failure. Data From the GWTG-HF (Get With The Guidelines-Heart Failure) Registry

Journal of the American College of Cardiology

Volumn 53, Issue 5, 2009, Pages 416-422

  Shah, Bimal ^a   Hernandez, Adrian F ^a   Liang, Li ^a   Al Khatib, Sana M ^a   Yancy, Clyde W ^b   Fonarow, Gregg C ^c   Peterson, Eric D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

heart failure; hospital; ICD; registry

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; HEALTH CARE QUALITY; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRIORITY JOURNAL;

AGED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; QUALITY OF HEALTH CARE; REGISTRIES; TREATMENT OUTCOME;

EID: 58549089344     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.09.045     Document Type: Article

References (20)

1. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
2. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
3. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
4. Curtis L.H., Al-Khatib S.M., Shea A.M., Hammill B.G., Hernandez A.F., and Schulman K.A. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 298 (2007) 1517-1524
5. Hernandez A.F., Fonarow G.C., Liang L., et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 298 (2007) 1525-1532
6. Majumdar S.R., McAlister F.A., and Furberg C.D. From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol 43 (2004) 1738-1742
7. LaBresh K.A., Ellrodt A.G., Gliklich R., Liljestrand J., and Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 164 (2004) 203-209
8. LaBresh K.A., Gliklich R., Liljestrand J., Peto R., and Ellrodt A.G. Using "get with the guidelines" to improve cardiovascular secondary prevention. Jt Comm J Qual Saf 29 (2003) 539-550
9. Smaha L.A. The American Heart Association Get With The Guidelines program. Am Heart J 148 (2004) S46-S48
10. Fonarow G.C., Abraham W.T., Albert N.M., et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 148 (2004) 43-51
11. Curtis L.H., Griner M.A., Fonarow G.C., and Schulman K.A. Validity of a national heart failure quality of care registry: comparison of Medicare patients in OPTIMIZE-HF versus non-OPTIMIZE-HF hospitals. HA. Circulation 115 (2007) e595
12. American Hospital Association Data. http://www.ahadata.com/ahadata_app/index.jsp Accessed August 15, 2008
13. The Joint Commission performance measures. http://www.jointcommission.org/NR/rdonlyres/CFFFD7BD-7E4C-497D-AFDE-599D70CB589B/0/NHQM_v24bb_PDF_4_1_2008.zip Accessed August 15, 2008
14. Bonow R.O., Bennett S., Casey Jr. D.E., et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. J Am Coll Cardiol 46 (2005) 1144-1178
15. Alter D.A., Austin P.C., and Tu J.V. Community factors, hospital characteristics and inter-regional outcome variations following acute myocardial infarction in Canada. Can J Cardiol 21 (2005) 247-255
16. Cutler D.M., and Huckman R.S. Technological development and medical productivity: the diffusion of angioplasty in New York state. J Health Econ 22 (2003) 187-217
17. Ho V. Certificate of need, volume, and percutaneous transluminal coronary angioplasty outcomes. Am Heart J 147 (2004) 442-448
18. U.S. Food and Drug Administration Center for Devices and Radiological Health. Boston Scientific/Guidant Recall: Questions & Answers (April 10, 2007). http://www.fda.gov/cdrh/news/guidantrecall.html Accessed August 15, 2008
19. U.S. Food and Drug Administration Center for Devices and Radiological Health. Class I Recall: Medical Device Recalls: Micro Jewel II and GEM DR ICDs. http://www.fda.gov/cdrh/recalls/recall-040404.html Accessed August 15, 2008
20. Brown N., Melville M., Gray D., et al. Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis. Heart 81 (1999) 598-602